

# Djibouti

Population 2016

<1 million

Estimates of TB burden*, 2016	Number (thousands)	Rate (per 100 000 population)
Mortality (excludes HIV+TB)	0.33 (0.21–0.47)	35 (22–50)
Mortality (HIV+TB only)	0.035 (0.025–0.046)	3.7 (2.7–4.9)
Incidence (includes HIV+TB)	3.2 (2.4–4)	335 (256–423)
Incidence (HIV+TB only)	0.17 (0.13–0.21)	18 (13–22)
Incidence (MDR/RR-TB)**	0.17 (0.093–0.25)	18 (9.8–27)

## Estimated TB incidence by age and sex (thousands)\*, 2016

	0-14 years	> 14 years	Total
Females	0.25 (0.19–0.31)	0.86 (0.65–1.1)	1.1 (0.84–1.4)
Males	0.29 (0.21–0.36)	1.8 (1.3–2.2)	2 (1.5–2.5)
Total	0.54 (0.4–0.67)	2.6 (2–3.3)	3.2 (2.4–4)

## TB case notifications, 2016

Total cases notified	2 526
Total new and relapse	2 522
- % tested with rapid diagnostics at time of diagnosis	56%
- % with known HIV status	89%
- % pulmonary	61%
- % bacteriologically confirmed among pulmonary	79%

## Universal health coverage and social protection

TB treatment coverage (notified/estimated incidence), 2016	80% (63–100)
TB patients facing catastrophic total costs	
TB case fatality ratio (estimated mortality/estimated incidence), 2016	0.12 (0.07–0.17)

## TB/HIV care in new and relapse TB patients, 2016

	Number	(%)
Patients with known HIV-status who are HIV-positive	118	5%
- on antiretroviral therapy	90	76%

Drug-resistant TB care, 2016	New cases	Previously treated cases	Total number***
Estimated MDR/RR-TB cases among notified pulmonary TB cases			110 (76–150)
Estimated % of TB cases with MDR/RR-TB	4.3% (2.5–7.3)	35% (25–47)	
% notified tested for rifampicin resistance	43%	60%	2 008
MDR/RR-TB cases tested for resistance to second-line drugs			0
Laboratory-confirmed cases		MDR/RR-TB: 80, XDR-TB: 6	
Patients started on treatment ****		MDR/RR-TB: 71, XDR-TB: 6	

Treatment success rate and cohort size	Success	Cohort
New cases registered in 2015	85%	1 042
Previously treated cases registered in 2015	71%	136
HIV-positive TB cases registered in 2015		
MDR/RR-TB cases started on second-line treatment in 2014		
XDR-TB cases started on second-line treatment in 2014		

## TB preventive treatment, 2016

% of HIV-positive people (newly enrolled in care) on preventive treatment	21%
% of children (aged < 5) household contacts of bacteriologically-confirmed TB cases on preventive treatment	6.4% (5.9–7)

## TB financing, 2017

National TB budget (US\$ millions)	1.1
Funding source: domestic, 100% international, 0% unfunded	

\* Ranges represent uncertainty intervals


\*\* MDR is TB resistant to rifampicin and isoniazid; RR is TB resistant to rifampicin

\*\*\* Includes cases with unknown previous TB treatment history

\*\*\*\* Includes patients diagnosed before 2016 and patients who were not laboratory-confirmed


# Tuberculosis profile

(Rate per 100 000 population per year)




— Mortality (excludes HIV+TB)

(Rate per 100 000 population per year)




— Incidence  
— Notified (new and relapse)  
— Incidence (HIV+TB only)

## Notified cases by age group and sex, 2016



## Treatment success rate (%)



— New cases  
— Previously treated cases  
— HIV-positive — MDR/RR-TB — XDR-TB

## Total budget (US\$ millions)

